110 related articles for article (PubMed ID: 18448338)
1. Demonstration of direct binding of cIAP1 degradation-promoting bestatin analogs to BIR3 domain: Synthesis and application of fluorescent bestatin ester analogs.
Sato S; Aoyama H; Miyachi H; Naito M; Hashimoto Y
Bioorg Med Chem Lett; 2008 Jun; 18(11):3354-8. PubMed ID: 18448338
[TBL] [Abstract][Full Text] [Related]
2. Degradation-promoters of cellular inhibitor of apoptosis protein 1 based on bestatin and actinonin.
Sato S; Tetsuhashi M; Sekine K; Miyachi H; Naito M; Hashimoto Y; Aoyama H
Bioorg Med Chem; 2008 Apr; 16(8):4685-98. PubMed ID: 18313309
[TBL] [Abstract][Full Text] [Related]
3. Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins.
Itoh Y; Ishikawa M; Naito M; Hashimoto Y
J Am Chem Soc; 2010 Apr; 132(16):5820-6. PubMed ID: 20369832
[TBL] [Abstract][Full Text] [Related]
4. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein.
Okuhira K; Ohoka N; Sai K; Nishimaki-Mogami T; Itoh Y; Ishikawa M; Hashimoto Y; Naito M
FEBS Lett; 2011 Apr; 585(8):1147-52. PubMed ID: 21414315
[TBL] [Abstract][Full Text] [Related]
5. Small molecules destabilize cIAP1 by activating auto-ubiquitylation.
Sekine K; Takubo K; Kikuchi R; Nishimoto M; Kitagawa M; Abe F; Nishikawa K; Tsuruo T; Naito M
J Biol Chem; 2008 Apr; 283(14):8961-8. PubMed ID: 18230607
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for bivalent Smac-mimetics recognition in the IAP protein family.
Cossu F; Milani M; Mastrangelo E; Vachette P; Servida F; Lecis D; Canevari G; Delia D; Drago C; Rizzo V; Manzoni L; Seneci P; Scolastico C; Bolognesi M
J Mol Biol; 2009 Sep; 392(3):630-44. PubMed ID: 19393243
[TBL] [Abstract][Full Text] [Related]
7. Modulation of RIP1 ubiquitylation and distribution by MeBS to sensitize cancer cells to tumor necrosis factor α-induced apoptosis.
Kim S; Ohoka N; Okuhira K; Sai K; Nishimaki-Mogami T; Naito M
Cancer Sci; 2010 Nov; 101(11):2425-9. PubMed ID: 20825417
[TBL] [Abstract][Full Text] [Related]
8. Use of azidobestatin as a photoaffinity label to identify the active site peptide of leucine aminopeptidase.
Taylor A; Peltier CZ; Jahngen EG; Laxman E; Szewczuk Z; Torre FJ
Biochemistry; 1992 Apr; 31(16):4141-50. PubMed ID: 1567860
[TBL] [Abstract][Full Text] [Related]
9. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination.
Chang YF; Cheng CM; Chang LK; Jong YJ; Yuo CY
Biochem Biophys Res Commun; 2006 Apr; 342(4):1022-6. PubMed ID: 16510124
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bovine lens leucine aminopeptidase by bestatin: number of binding sites and slow binding of this inhibitor.
Taylor A; Peltier CZ; Torre FJ; Hakamian N
Biochemistry; 1993 Jan; 32(3):784-90. PubMed ID: 8422382
[TBL] [Abstract][Full Text] [Related]
11. Re-refinement of the X-ray crystal structure of bovine lens leucine aminopeptidase complexed with bestatin.
Kim H; Burley SK; Lipscomb WN
J Mol Biol; 1993 Apr; 230(3):722-4. PubMed ID: 8478928
[TBL] [Abstract][Full Text] [Related]
12. The role of bestatin, an inhibitor of cell surface proteases, in the interaction of serum with untransformed cells in culture.
Koren R; Bercovitz H; Umezawa H; Müller WE
J Antibiot (Tokyo); 1981 Jan; 34(1):90-4. PubMed ID: 7251513
[TBL] [Abstract][Full Text] [Related]
13. The structure of the BIR3 domain of cIAP1 in complex with the N-terminal peptides of SMAC and caspase-9.
Kulathila R; Vash B; Sage D; Cornell-Kennon S; Wright K; Koehn J; Stams T; Clark K; Price A
Acta Crystallogr D Biol Crystallogr; 2009 Jan; 65(Pt 1):58-66. PubMed ID: 19153467
[TBL] [Abstract][Full Text] [Related]
14. Effect of bestatin on mouse immune system and experimental murine tumors.
Ishizuka M; Masuda T; Kanbayashi N; Fukasawa S; Takeuchi T; Aoyagi T; Umezawa H
J Antibiot (Tokyo); 1980 Jun; 33(6):642-52. PubMed ID: 7419475
[TBL] [Abstract][Full Text] [Related]
15. Development of bestatin-based activity-based probes for metallo-aminopeptidases.
Harbut MB; Velmourougane G; Reiss G; Chandramohanadas R; Greenbaum DC
Bioorg Med Chem Lett; 2008 Nov; 18(22):5932-6. PubMed ID: 18823778
[TBL] [Abstract][Full Text] [Related]
16. Progress in the development of bestatin analogues as aminopeptidases inhibitors.
Chen L; Teng Y; Xu W
Curr Med Chem; 2011; 18(7):964-76. PubMed ID: 21254977
[TBL] [Abstract][Full Text] [Related]
17. Leucine aminopeptidase: bestatin inhibition and a model for enzyme-catalyzed peptide hydrolysis.
Burley SK; David PR; Lipscomb WN
Proc Natl Acad Sci U S A; 1991 Aug; 88(16):6916-20. PubMed ID: 1871107
[TBL] [Abstract][Full Text] [Related]
18. Mitogenic effect of bestatin on lymphocytes.
Ishizuka M; Sato J; Sugiyama Y; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1980 Jun; 33(6):653-62. PubMed ID: 7419476
[TBL] [Abstract][Full Text] [Related]
19. Bestatin inhibition of human tissue carnosinase, a non-specific cytosolic dipeptidase.
Peppers SC; Lenney JF
Biol Chem Hoppe Seyler; 1988 Dec; 369(12):1281-6. PubMed ID: 3242551
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic implications of the inhibition of peptidases by amino aldehydes and bestatin.
Frick L; Wolfenden R
Biochim Biophys Acta; 1985 Jul; 829(3):311-8. PubMed ID: 3890953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
